公开(公告)号：US20080279859A1

公开(公告)日：2008-11-13

申请号：US11943770

申请日：2007-11-21

Applicant: Mario Mezler ,  Achim Moeller ,  Reinhold Mueller ,  Bernhard K. Mueller ,  Tariq Ghayur ,  Eve H. Barlow ,  Martin Schmidt ,  Axel Meyer ,  Nicole E. Teusch

Inventor： Mario Mezler ,  Achim Moeller ,  Reinhold Mueller ,  Bernhard K. Mueller ,  Tariq Ghayur ,  Eve H. Barlow ,  Martin Schmidt ,  Axel Meyer ,  Nicole E. Teusch

IPC: A61K39/395 ,  C07K16/18 ,  C12N5/06 ,  C12N15/11 ,  C12N15/00 ,  A61P25/00 ,  C12N5/04 ,  C12N1/14 ,  C12P21/04

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Abstract translation: 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。

公开(公告)号：US20070071675A1

公开(公告)日：2007-03-29

申请号：US11507050

申请日：2006-08-18

Applicant: Chengbin Wu ,  Tariq Ghayur ,  Richard Dixon ,  Jochen Salfeld

Inventor： Chengbin Wu ,  Tariq Ghayur ,  Richard Dixon ,  Jochen Salfeld

IPC: A61K51/00 ,  C07H21/04 ,  C12P21/06 ,  C12N1/21 ,  C12N1/18 ,  C12N5/06

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/42 ,  A61K47/48384 ,  A61K47/6803 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/244 ,  C07K16/245 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/40 ,  C07K16/46 ,  C07K16/467 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/64 ,  C07K2317/76 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，特别涉及其用于预防和/或治疗急性和慢性炎症和其它疾病的用途。

公开(公告)号：US20060275288A1

公开(公告)日：2006-12-07

申请号：US11335387

申请日：2006-01-19

Applicant: Nelson Grihalde ,  Christine Collins ,  Andrea Pellacani ,  Tariq Ghayur

Inventor： Nelson Grihalde ,  Christine Collins ,  Andrea Pellacani ,  Tariq Ghayur

IPC: A61K39/395 ,  C07K16/28

CPC classification number: C07K16/26 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/77

Abstract: The subject invention relates to monoclonal antibodies that have the ability to bolster the function of the GLP-1 receptor and may therefore have utility in the treatment of mammalian metabolic disorders such as, for example, diabetes. In particular, the invention describes the generation of fully human monoclonal antibodies made against extracellular domains of the human GLP-1 receptor which are capable of binding the intact receptor and activating it in a manner similar to the native ligand. Additionally, the invention describes methods used to generate and develop allosteric modulator antibodies of the human GLP-1 receptor with potential therapeutic uses.

Abstract translation: 本发明涉及具有增强GLP-1受体功能的能力的单克隆抗体，因此可用于治疗哺乳动物代谢紊乱，例如糖尿病。 特别地，本发明描述了产生针对人GLP-1受体细胞外结构域的完全人单克隆抗体，其能够结合完整受体并以类似于天然配体的方式活化它。 此外，本发明描述了用于产生和开发具有潜在治疗用途的人GLP-1受体的变构调节剂抗体的方法。

公开(公告)号：US08853365B2

公开(公告)日：2014-10-07

申请号：US13331422

申请日：2011-12-20

Applicant: Chengbin Wu ,  Dominic J. Ambrosi ,  Chung-ming Hsieh ,  Tariq Ghayur

Inventor： Chengbin Wu ,  Dominic J. Ambrosi ,  Chung-ming Hsieh ,  Tariq Ghayur

IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  C07K16/24 ,  C07K1/00 ,  A61K39/00

CPC classification number: A61K39/395 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/245 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，具体涉及用于预防，诊断和/或治疗疾病的用途。

公开(公告)号：US08841417B2

公开(公告)日：2014-09-23

申请号：US13107439

申请日：2011-05-13

Applicant: Chengbin Wu ,  Dominic J. Ambrosi ,  Chung-ming Hsieh ,  Tariq Ghayur

Inventor： Chengbin Wu ,  Dominic J. Ambrosi ,  Chung-ming Hsieh ,  Tariq Ghayur

IPC: A61K38/00 ,  C07K14/545 ,  C07K16/24 ,  A61K39/395 ,  A61K47/48 ,  A61K45/06 ,  G01N33/68

CPC classification number: C07K16/245 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/007 ,  A61K9/0085 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6879 ,  C07K14/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869 ,  G01N2333/545 ,  G01N2800/00 ,  Y02A50/385 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/412 ,  Y02A50/463 ,  Y02A50/478 ,  Y02A50/481

Abstract: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

Abstract translation: 结合IL-1α和IL-1和bgr的蛋白质 描述其用于治疗，预防和诊断IL-1相关疾病和用于检测IL-1α和IL-1和bgr的组合物和方法中的用途; 在细胞，组织，样品和组合物中。

公开(公告)号：US20140213768A1

公开(公告)日：2014-07-31

申请号：US14023330

申请日：2013-09-10

Applicant: Chengbin WU ,  Tariq GHAYUR ,  Richard W. DIXON ,  Jochen G. SALFELD

Inventor： Chengbin WU ,  Tariq GHAYUR ,  Richard W. DIXON ,  Jochen G. SALFELD

IPC: C07K16/46

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/42 ,  A61K47/6803 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/244 ,  C07K16/245 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/40 ,  C07K16/46 ,  C07K16/467 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/64 ,  C07K2317/76 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

公开(公告)号：US20130236458A1

公开(公告)日：2013-09-12

申请号：US13729645

申请日：2012-12-28

Applicant: Chung-Ming HSIEH ,  Tariq Ghayur ,  Carrie L. Goodreau

Inventor： Chung-Ming HSIEH ,  Tariq Ghayur ,  Carrie L. Goodreau

IPC: C07K16/46 ,  A61K45/06 ,  G01N33/68 ,  A61K39/395

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/244 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/54 ,  G01N2333/5437

Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US20120258108A1

公开(公告)日：2012-10-11

申请号：US13286707

申请日：2011-11-01

Applicant: Tariq Ghayur ,  Junjian Liu ,  Jijie Gu ,  Maria C. Harris

Inventor： Tariq Ghayur ,  Junjian Liu ,  Jijie Gu ,  Maria C. Harris

IPC: C07K16/46 ,  C12N15/13 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  G01N33/53 ,  C12N5/10 ,  C12N1/11 ,  C12N1/15 ,  C12N1/21 ,  C12N1/19 ,  C12P21/02 ,  C07K17/00 ,  C12N15/63

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/241 ,  C07K16/26 ,  C07K16/2863 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/567 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412

Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.

公开(公告)号：US20120201746A1

公开(公告)日：2012-08-09

申请号：US13333545

申请日：2011-12-21

Applicant: JUNJIAN LIU ,  JIJIE GU ,  TARIQ GHAYUR ,  CHARLES W. HUTCHINS

Inventor： JUNJIAN LIU ,  JIJIE GU ,  TARIQ GHAYUR ,  CHARLES W. HUTCHINS

IPC: A61K51/00

CPC classification number: C07K16/2863 ,  C07K16/00 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The invention provides compositions, methods, and kits related to half-Ig binding proteins that include a functional antibody binding site and a CH3 domain wherein the CH3 domain includes at least one mutation to inhibit CH3-CH3 dimerization.

Abstract translation: 本发明提供了与包含功能性抗体结合位点和CH3结构域的半Ig结合蛋白相关的组合物，方法和试剂盒，其中CH3结构域包括至少一个抑制CH3-CH3二聚化的突变。

公开(公告)号：US20120129853A1

公开(公告)日：2012-05-24

申请号：US13301898

申请日：2011-11-22

Applicant: Steven Elmore ,  Andrew Souers ,  Li Chun Wang ,  Tariq Ghayur ,  Stuart J. Perper

Inventor： Steven Elmore ,  Andrew Souers ,  Li Chun Wang ,  Tariq Ghayur ,  Stuart J. Perper

IPC: A61K31/5377 ,  A61P37/06 ,  A61P13/12 ,  A61K31/496

CPC classification number: A61K31/5377 ,  A61K31/496

Abstract: This invention pertains to methods of treating systemic lupus erythematosus, lupus nephritis or Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-xL.

Abstract translation: 本发明涉及用选择性抑制Bcl-2抗凋亡蛋白活性的化合物治疗系统性红斑狼疮，狼疮肾炎或干燥综合征的方法。 具体地，本发明涉及用选择性抑制Bcl-2蛋白活性的化合物治疗，对抑制其它BCL-2家族蛋白（包括Bcl-xL）活性的亲和性较小。